Medical therapy with dopamine agonist is very effective in controlling prolactin serum levels and it usually represents the first therapeutic choice for prolactin secreting pituitary adenomas. However, many patients present increase of prolactinemia after withdrawal of medical therapy which consequently should be taken for long time; other present intolerance to medical therapy; women with pregnancy need to withdraw dopamine agonists with consequent potential related problems: in these patients transsphenoidal surgery can be requested. The presented study concerns the efficacy of transsphenoidal surgery in patients affected by microprolactinoma after treatment with medical therapy for different periods of time. Different postsurgical result...
Context: The improved remission and complication rates of current transsphenoidal surgery warrant re...
Dopamine agonists are the treatment of choice for prolactinomas and symptomatic idiopathic hyperprol...
Prolactinomas account for approximately 50% of all pituitary adenomas coming to medical attention an...
Medical therapy with dopamine agonist is very effective in controlling prolactin serum levels and it...
Despite the fact that consensus guidelines recommend long-term dopamine agonist (DA) therapy as a fi...
Aims and Objectives: To report hormonal outcome after surgery in a special subgroup of prolactinomas...
AIMS: Reported cure rates following trans-sphenoidal surgery for microprolactinoma are variable and ...
(Correspondence should be addressed to J A H Wass) Aims: Reported cure rates following trans-sphenoi...
The objectives of the treatment of hyperprolactinaemia are to suppress excessive hormone secretion a...
Objective. The aim of this study was to explore the long-term outcomes of surgery for transsphenoida...
Background: Prolactinomas represent a unique challenge for endocrinologists and neurosurgeons. Consi...
The dilemma of whether to apply surgical or drug treatment to prolactinomas has been ongoing for the...
Copyright © 2015 Ivan Kruljac et al. This is an open access article distributed under the Creative C...
While dopamine-agonists are the first-line approach in treating prolactinomas, surgery can be consid...
The dilemma of whether to apply surgical or drug treatment to prolactinomas has been ongoing for the...
Context: The improved remission and complication rates of current transsphenoidal surgery warrant re...
Dopamine agonists are the treatment of choice for prolactinomas and symptomatic idiopathic hyperprol...
Prolactinomas account for approximately 50% of all pituitary adenomas coming to medical attention an...
Medical therapy with dopamine agonist is very effective in controlling prolactin serum levels and it...
Despite the fact that consensus guidelines recommend long-term dopamine agonist (DA) therapy as a fi...
Aims and Objectives: To report hormonal outcome after surgery in a special subgroup of prolactinomas...
AIMS: Reported cure rates following trans-sphenoidal surgery for microprolactinoma are variable and ...
(Correspondence should be addressed to J A H Wass) Aims: Reported cure rates following trans-sphenoi...
The objectives of the treatment of hyperprolactinaemia are to suppress excessive hormone secretion a...
Objective. The aim of this study was to explore the long-term outcomes of surgery for transsphenoida...
Background: Prolactinomas represent a unique challenge for endocrinologists and neurosurgeons. Consi...
The dilemma of whether to apply surgical or drug treatment to prolactinomas has been ongoing for the...
Copyright © 2015 Ivan Kruljac et al. This is an open access article distributed under the Creative C...
While dopamine-agonists are the first-line approach in treating prolactinomas, surgery can be consid...
The dilemma of whether to apply surgical or drug treatment to prolactinomas has been ongoing for the...
Context: The improved remission and complication rates of current transsphenoidal surgery warrant re...
Dopamine agonists are the treatment of choice for prolactinomas and symptomatic idiopathic hyperprol...
Prolactinomas account for approximately 50% of all pituitary adenomas coming to medical attention an...